...

Module

Treatment Options After Hormone, Anthracycline, and Taxane Therapy in Advanced/Metastatic Breast Cancer

Source: Beyond Taxane Therapy: The Emerging Role of Epothilones in Metastatic Breast Cancer

Treatment Options After Hormone, Anthracycline, and Taxane Therapy in Advanced/Metastatic Breast Cancer


Program Director: Andrew D. Seidman, MD

Faculty:

Edith A. Perez, MD
  • Edith A. Perez, MD

CREDIT INFORMATION

Release Date: 12/7/05

Expiration Date: 12/6/06


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the efficacy and safety of current treatment options for women with metastatic breast cancer
  • Review clinical data on treatment options for patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes
  • Recount data from phase I/II/III clinical trials of investigational agents in metastatic breast cancer

Topics covered include:

  • Goals of Therapy in Metastatic Breast Cancer
  • After Anthracyclines and Taxanes: Multiple Options
  • Capecitabine in Taxane-Pretreated Metastatic Breast Cancer
  • Gemcitabine in Metastatic Breast Cancer Refractory to Anthracyclines or Taxanes
  • Nanoparticle Paclitaxel (ABI-007) in Taxane-Refractory and Heavily Pretreated Metastatic Breast Cancer
  • Vinorelbine in Refractory Metastatic Breast Cancer
  • Vinflunine After Anthracycline-Taxane Failure in Metastatic Breast Cancer
  • Targeting Dysregulated Pathways With Novel Agents
  • Agents Targeting the VEGF Pathway
  • Ixabepilone in Metastatic Breast Cancer
  • Active NCCTG Trials for Metastatic Breast Cancer: Prior Anthracyclines and/or Taxanes
  • Conclusion
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.